Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks Japanese Distribution Deal

NEW YORK (GenomeWeb News) – Following its first distribution deal for Asia, Link Technologies today announced another deal covering that region, this time with Japanese firm GeneDesign

Under the terms of the agreement, GeneDesign will represent Link throughout Japan. The agreement comes about a month after Link forged a distribution agreement with Zirench Technology covering China.

"By working with GeneDesign, we will be able to provide local access to our high quality products and offer our expert support services to customers throughout Japan," Link CEO John Bremner said in a statement. "This level of accessibility is something we are very keen to continue to develop within Asia and worldwide, and forms part of our ongoing strategic plans for development and growth."

Financial and other terms were not disclosed.

Link is based in Bellshill, Scotland and supplies specialty reagents for oligonucleotide synthesis and modification. GeneDesign is a contract manufacturing organization headquartered in Osaka, Japan. It also provides contract research organization services focused on oligonucleotide chemistry.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.